PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive vectorized gene therapies with minimally-invasive delivery technology, is pleased to announce the ...

Age-related macular degeneration (AMD) is a leading cause of vision loss among people aged 50 and older. While treatments for the wet form of AMD have shown promise, the dry form, which accounts for ...

Companies across the globe are diligently working toward developing novel Dry Age Macular Degeneration treatment therapies ...

New treatments for macular degeneration may help preserve your eyesight for longer, without the need for frequent injections. Some of these treatments include retinal gene therapy and the "port" ...

Dry age-related macular degeneration (AMD) management is currently based on regular follow-up for early detection of choroidal neovascularization (CNV), addressing the risk factors and prescribing ...

GENEVA--(BUSINESS WIRE)-- Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced its intention to acquire LumiThera, Inc., a leader in light-based ...

Cognition Therapeutics, Inc. announced the publication of a manuscript highlighting research on zervimesine (CT1812), a candidate for treating dry age-related macular degeneration (dry AMD). The study ...

Potential for Vonaprument to Be the First Treatment Approved in Europe and the U.S. for Dry AMD with Geographic Atrophy Based on Protection of Visual Acuity and Structural Measures BRISBANE, Calif., ...

Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended as an early intervention to slow disease progression in patients affected with Stargardt Disease (STGD1) and Dry ...

Age-related macular degeneration (AMD) remains a leading cause of vision loss globally, with significant advancements in treatment options for both dry and wet AMD. As highlighted by Huang and ...

AMD is the leading cause of central vision loss in the elderly, affecting 200 million people worldwide. AMD's pathogenesis is complex, and the disease still represents a high unmet medical need. Dry ...